Standard Operating Procedure for Review of Contraindications Warnings and Precautions Text
| Department | Regulatory Affairs |
| SOP No. | RA/2026/759 |
| Supersedes | NA |
| Page No. | 1 of X |
| Issue Date | 16/04/2026 |
| Effective Date | 16/04/2026 |
| Review Date | 16/04/2028 |
Purpose
This Standard Operating Procedure (SOP) defines the systematic process for the review and approval of contraindications, warnings, and precautions text incorporated in labelling, artwork, and product information documents. The objective is to ensure that all safety-related statements are accurate, up-to-date, compliant with regulatory guidelines, and consistently communicated across all product information to safeguard patient safety and support regulatory submissions.
Scope
This SOP applies to all activities related to the review, verification, and approval of contraindications, warnings, and precautions text for medicinal products within Regulatory Affairs. It covers labelling materials, artwork, packaging inserts, patient information leaflets, electronic submissions, and other product information documents. The scope includes all dosage forms, therapeutic categories, and markets managed by the organization. Excluded are manufacturing process parameters, equipment operation, and clinical data generation activities, which are governed under separate SOPs.
Responsibilities
- Regulatory Affairs Reviewers: Perform detailed assessment of contraindications, warnings, and precautions statements for accuracy and regulatory compliance.
- Quality Assurance (QA): Oversee and verify compliance with internal procedures and regulatory requirements.
- Medical Affairs/Pharmacovigilance: Provide clinical safety input and ensure alignment with latest safety data.
- Document Control: Manage version control and archival of reviewed documents.
- Department Head – Regulatory Affairs: Supervises the review process and coordinates cross-functional inputs.
Accountability
The Head of Regulatory Affairs holds overall accountability for implementation, compliance, and maintenance of this SOP. This role ensures periodic review of process effectiveness, escalates issues to senior management, and approves corrective actions as necessary.
Procedure
1. Preparation and Preliminary Checks: Prior to review, collect the latest version of labelling and product information documents requiring evaluation. Verify the associated dossier and safety data are current. Confirm availability of applicable regulatory guidelines for target markets.
2. Review of Content:
- Compare the contraindications, warnings, and precautions text against relevant internal safety data, clinical evaluation reports, and pharmacovigilance updates.
- Benchmark content with current regulatory requirements such as ICH guidelines, FDA, EMA, or local health authorities.
- Ensure clarity, consistency, and proper terminology in the text as per company style and regulatory expectations.
- Flag inconsistencies, omissions, or outdated statements for investigation.
3. Cross-Functional Consultation: Engage Medical Affairs and Pharmacovigilance experts to validate safety information and clinical relevance. Where applicable, consult Quality Assurance for procedural compliance checks.
4. Documentation of Review: Document detailed findings in the Review Checklist (Document 1) specifying each section’s compliance status and remarks. Record all amendments recommended and rationale for changes.
5. Approval Process: Submit reviewed documents and checklist to the Regulatory Affairs Manager for approval. Address any queries or further revisions promptly. Once accepted, update the controlled document repository with the approved version.
6. Implementation and Communication: Coordinate with Artwork and Labelling teams to implement approved text changes in production artwork and packaging. Confirm implementation via sign-off records.
7. Record Retention: Retain all review checklists, correspondence, approval records, and final versions in the regulatory documentation system as per document retention policy.
8. Handling Deviations and Updates: In case of deviations or emerging safety data requiring urgent updates, initiate expedited review as per Change Control procedures. Notify relevant stakeholders of changes.
This procedure ensures a thorough, compliant, and auditable review process that maintains the accuracy and regulatory readiness of all safety-related labelling statements.
Abbreviations
- QA – Quality Assurance
- ICH – International Council for Harmonisation
- FDA – Food and Drug Administration
- EMA – European Medicines Agency
- SOP – Standard Operating Procedure
- RA – Regulatory Affairs
- Pv – Pharmacovigilance
Documents
- Review Checklist for Contraindications, Warnings and Precautions Text (Annexure-1)
- Approval Form for Labelling Safety Statements (Annexure-2)
- Change Control Request for Safety Text Updates (Annexure-3)
References
- ICH M4E: Common Technical Document for the Registration of Pharmaceuticals for Human Use
- FDA Guidance for Industry: Labeling for Human Prescription Drug and Biological Products
- EMA Guideline on the Readability of the Label and Package Leaflet of Medicinal Products for Human Use
- Company Quality Manual and Document Control Procedures
- Pharmacovigilance SOPs and Safety Data Management Guidelines
Version
1.0
Approval
| Prepared By | |
| Checked By | |
| Approved By |
Annexures
Annexure-1: Review Checklist for Contraindications, Warnings and Precautions Text
| Document No. | RA-RCL-001 |
| Review Date | 15/04/2026 |
| Product Name | SampleProduct X |
| Dosage Form | Tablet |
| Reviewer | Regulatory Reviewer |
Checklist Items:
| Section | Compliance Status | Comments |
|---|---|---|
| Contraindications Text | Compliant | Aligned with latest clinical data and guidelines |
| Warnings Text | Compliant | Clear and unambiguous statements present |
| Precautions Text | Non-compliant | Update recommended to reflect new safety findings |
| Terminology Consistency | Compliant | Terminology matches company style |
| Regulatory Alignment | Compliant | Meets FDA and EMA labeling requirements |
Summary of Actions: Update precautions text with latest safety data and re-review.
Reviewer Signature: ____________________ Date: 15/04/2026
Annexure-2: Approval Form for Labelling Safety Statements
| Form No. | RA-APP-005 |
| Product | SampleProduct X |
| Version | V2.3 |
| Approval Date | 16/04/2026 |
| Approved By | Regulatory Manager |
Approval Statement:
The reviewed contraindications, warnings, and precautions text for SampleProduct X has been evaluated against the current safety data and regulatory criteria. This version is approved for implementation into labelling and promotional materials.
Signature: ____________________ Date: 16/04/2026
Annexure-3: Change Control Request for Safety Text Updates
| Change Control No. | CC-RA-2026-014 |
| Request Date | 20/04/2026 |
| Initiator | Regulatory Affairs |
| Description of Change | Update to Precautions text based on recent pharmacovigilance findings. |
| Impact Assessment | Minimal impact on labelling timelines. No effect on manufacturing process. |
| Approval Status | Pending |
Requested By: ____________________ Date: 20/04/2026
Approved By: ____________________ Date:
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
| 16/04/2026 | 1.0 | Initial issue | New SOP creation |